All News
Filter News
Found 809,162 articles
-
Shionogi Announces Strategic Re-Organization of U.S. Executive Leadership
6/1/2022
Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd. based in New Jersey, has announced a strategic executive leadership re-organization and expansion of the company’s Executive Committee with the following changes effective July 1, 2022:.
-
Abivax Phase 2a Study Results of Obefazimod (ABX464) in Rheumatoid Arthritis Published in the Journal "Annals of the Rheumatic Diseases" and Selected for Presentation at EULAR 2022
6/1/2022
Abivax SA announces that a scientific article on its phase 2a clinical study results for the treatment of moderate to severe active rheumatoid arthritis with obefazimod has been published in the renowned peer-reviewed journal "Annals of the Rheumatic Diseases ".
-
MolecuLight Added to the ISWCAP 2022 Consensus Guidelines for Optimising Prevention of Surgical Wound Complications
6/1/2022
MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced that it has been added to the new 2022 Consensus Guidelines of the International Surgical Wound Complications Advisory Panel.
-
Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director
6/1/2022
Innovent Biologics, Inc. announced the appointment of Mr. Gary Zieziula as an independent non-executive director of the board of directors and a member of the audit committee of the Board and the strategy committee of the Board.
-
Rockwell Medical Regains Compliance with Nasdaq Listing Requirements - June 01, 2022
6/1/2022
Rockwell Medical, Inc. announced that it received notice from The NASDAQ Stock Market LLC on May 31, 2022 informing Rockwell Medical that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on The NASDAQ Capital Market.
-
Kronos Bio Announces Participation in Upcoming Investor Conferences - June 01, 2022
6/1/2022
Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, announced that President and Chief Executive Officer Norbert Bischofberger, Ph.D., will participate in fireside chats at the following investor conferences:
-
Viridian Therapeutics to Participate in June 2022 Investor Conferences
6/1/2022
Viridian Therapeutics, Inc. announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in two fireside chats at the Jefferies Healthcare Conference being held in New York on June 8 -10, 2022 and the JMP Securities Life Sciences Conference in New York on June 15 - 16, 2022.
-
Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
6/1/2022
RELIEF THERAPEUTICS Holding SA announced that, at its Annual General Meeting of shareholders held on Tuesday, May 31, 2022, the proposed resolutions described in the AGM invitation and detailed below were approved by more than 85 percent of the represented votes.
-
Dr. Funda Suer Joins Quadrant Biosciences as EVP of Clinical Diagnostics and CLIA Laboratory Director
6/1/2022
Quadrant Biosciences Inc., a developer of novel molecular diagnostics, announced that Dr. Funda Suer has joined the company as Executive Vice President of Clinical Diagnostics and CLIA Laboratory Director.
-
TPX-100: OrthoTrophix Presents the Latest Clinical Data at BIO 2022
6/1/2022
OrthoTrophix, Inc. announced that the Company will present the latest clinical data and registration plan of TPX-100 in knee osteoarthritis patients at BIO 2022.
-
Savara to Present at Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will present at the Jefferies Healthcare Conference on June 8, 2022 at 1:00 pm ET in New York City.
-
TFF Pharmaceuticals to Participate at the Jefferies Healthcare Conference
6/1/2022
TFF Pharmaceuticals, Inc. announced that President and CEO Glenn Mattes will be participating in the Jefferies Healthcare Conference being held June 8 – 10, 2022 in New York City.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2022
6/1/2022
Cytokinetics, Incorporated announced that on May 31, 2022 it granted stock options to purchase an aggregate of 179,100 shares of common stock to 23 new employees, whose employment commenced in May 2022, as a material inducement to their employment.
-
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2022
6/1/2022
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 40,000 shares of the company’s common stock to one new employee.
-
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences - June 01, 2022
6/1/2022
Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced that the company will participate in two upcoming in-person investor conferences.
-
Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome
6/1/2022
Neuronascent Inc, announced that the U.S. Food and Drug Administration granted “Orphan Drug Designation” for the company’s NNI-351 treatment of Fragile X Syndrome.
-
Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations
6/1/2022
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced a global call for entries for their inaugural Early Career Research Award.
-
Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance
6/1/2022
Mainz Biomed N.V. announced that it has successfully completed the conformity assessment of its internal processes to In Vitro Diagnostic Devices Regulation compliance which becomes mandatory from May 26, 2022.
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2022
6/1/2022
G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for 1,400 shares of G1’s common stock and 800 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
DermTech to Present at the William Blair Growth Stock Conference
6/1/2022
DermTech, Inc. announced that management is scheduled to present at the William Blair Growth Stock Conference on Wednesday, June 8, 2022 at 2:00 p.m. CT.